Cancer Research The Future of Cancer Research: Science and Patient Impact  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 56, 1517-1525, April 1, 1996]
© 1996 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Debiec-Rychter, M.
Right arrow Articles by King, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Debiec-Rychter, M.
Right arrow Articles by King, C. M.

Histological Localization of Messenger RNAs for Rat Acetyltransferases That Acetylate Serotonin and Genotoxic Arylamines1

Maria Debiec-Rychter2, Susan J. Land3 and Charles M. King4

Carcinogenesis Program, Karmanos Cancer Institute, Detroit, Michigan 48201-1379

Rat acetyltransferases (ATs) can acetylate the endogenous arylalkylamines tryptamine, 5-hydroxytryptamine (serotonin), and 5-methoxytryptamine, the immediate precursor of melatonin. The same enzymes also acetylate and activate exogenous, carcinogenic arylamines, thereby being immediately responsible for the generation of DNA adducts. Localization of AT transcripts in the pineal gland and in specific cells of the intestine, cerebral cortex, pituitary, and lung identifies cells that may be important to the neurotransmitter and hormonal roles of the tryptamine derivatives. Transcript localization in liver, mammary gland, Zymbal gland, kidney, forestomach, and bladder, as well as intestine and lung, identifies cells that may be at increased carcinogenic risk because they can convert N-hydroxylated arylamines to genotoxic metabolites. High specific expression is also observed in the reproductive organs of both the male and female, including the testes, epididymis, uterus, ovary, and fallopian tube. In addition to these diverse organs, which are consistent with possible roles of the enzyme in carcinogen metabolism, neurotransmission, or hormonal regulation, specific cells of the cornea, cilliary process of the eye, olfactory process, adrenal gland, exorbital lacrimal gland, and skin also exhibit highly specific expression of AT mRNAs for which one can only speculate as to their function. In virtually every case, the extent of labeling suggested that AT1 was expressed at levels that were orders of magnitude higher than those of AT2. Qualitative differences in the sites of mRNA of these two enzymes were seen only in the olfactory process, in which AT1 was expressed in both respiratory and olfactory epithelia as well as Bowman's cells, and AT2 was detected only in the latter cells. The available data support the conclusion that the ATs are likely to be involved both in the metabolic activation of exogenous carcinogenic amines as well as the metabolism of endogenous arylalkylamines that play important hormonal and neurotransmitter roles.

1 This contribution from the A. Alfred Taubman Facility for Environmental Carcinogenesis was supported by NIH Grants CA23386 and CA45639 and an institutional grant from the United Way.

2 Present address: Tumor Biology Laboratory, Department of Oncology, Paderewski 4, 93-509 Lodz, Poland.

3 To whom requests for reprints should be addressed, at Carcinogenesis Program, Karmanos Cancer Institute, 110 East Warren Avenue, Detroit, MI 48201-1379.

4 Present address: 110 Sixth Street, Wilmette, IL 60091.

Received 10/ 2/95. Accepted 2/ 1/96.




This article has been cited by other articles:


Home page
Toxicol PatholHome page
A. M. Jeffrey, M. J. Iatropoulos, and G. M. Williams
Nasal Cytotoxic and Carcinogenic Activities of Systemically Distributed Organic Chemicals
Toxicol Pathol, December 1, 2006; 34(7): 827 - 852.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
C. A. McQueen and B. Chau
Neonatal Ontogeny of Murine Arylamine N-Acetyltransferases: Implications for Arylamine Genotoxicity
Toxicol. Sci., June 1, 2003; 73(2): 279 - 286.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. Chang-Claude, S. Kropp, B. Jager, H. Bartsch, and A. Risch
Differential Effect of NAT2 on the Association between Active and Passive Smoke Exposure and Breast Cancer Risk
Cancer Epidemiol. Biomarkers Prev., August 1, 2002; 11(8): 698 - 704.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
A. Slominski and J. Wortsman
Neuroendocrinology of the Skin
Endocr. Rev., October 1, 2000; 21(5): 457 - 487.
[Abstract] [Full Text]


Home page
Toxicol SciHome page
K. F. Windmill, A. Gaedigk, P. de la M. Hall, H. Samaratunga, D. M. Grant, and M. E. McManus
Localization of N-Acetyltransferases NAT1 and NAT2 in Human Tissues
Toxicol. Sci., March 1, 2000; 54(1): 19 - 29.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
C. Y. Wang, M. Debiec-Rychter, H. A.J. Schut, P. Morse, R. F. Jones, C. Archer, C. M. King, and G. P. Haas
N-Acetyltransferase expression and DNA binding of N-hydroxyheterocyclic amines in human prostate epithelium
Carcinogenesis, August 1, 1999; 20(8): 1591 - 1596.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1996 by the American Association for Cancer Research.